Smith Salley & Associates Has Lifted Gilead Sciences (GILD) Position by $2.25 Million as Shares Declined; Osmium Partners Has Cut Its Cra Intl (Call) (CRAI) Position by $1.61 Million; Share Value Declined

February 15, 2018 - By Marguerite Chambers

Smith Salley & Associates increased its stake in Gilead Sciences Inc (GILD) by 114.59% based on its latest 2017Q3 regulatory filing with the SEC. Smith Salley & Associates bought 27,824 shares as the company’s stock declined 8.05% while stock markets rallied. The institutional investor held 52,105 shares of the health care company at the end of 2017Q3, valued at $4.22 million, up from 24,281 at the end of the previous reported quarter. Smith Salley & Associates who had been investing in Gilead Sciences Inc for a number of months, seems to be bullish on the $106.78 billion market cap company. The stock decreased 0.10% or $0.08 during the last trading session, reaching $81.74. About 3.07M shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since February 15, 2017 and is downtrending. It has underperformed by 38.50% the S&P500.

John H Lewis decreased its stake in Cra Intl Inc (Call) (CRAI) by 26.95% based on its latest 2017Q3 regulatory filing with the SEC. Osmium Partners Llc sold 39,300 shares as the company’s stock declined 10.22% while stock markets rallied. The hedge fund run by John H Lewis held 106,500 shares of the miscellaneous company at the end of 2017Q3, valued at $4.37 million, down from 145,800 at the end of the previous reported quarter. Osmium Partners Llc who had been investing in Cra Intl Inc (Call) for a number of months, seems to be less bullish one the $364.43 million market cap company. The stock increased 4.05% or $1.75 during the last trading session, reaching $44.94. About 11,993 shares traded. CRA International, Inc. (NASDAQ:CRAI) has risen 49.42% since February 15, 2017 and is uptrending. It has outperformed by 32.72% the S&P500.

Investors sentiment increased to 1.03 in Q3 2017. Its up 0.10, from 0.93 in 2017Q2. It increased, as 96 investors sold GILD shares while 488 reduced holdings. 127 funds opened positions while 474 raised stakes. 957.62 million shares or 2.06% more from 938.32 million shares in 2017Q2 were reported. Paradigm Financial Advsrs Limited invested in 0.31% or 8,723 shares. Spears Abacus Advsrs Ltd Liability accumulated 316,154 shares. Dubuque Bancshares Trust Comm reported 0.02% stake. Glenmede Tru Na accumulated 623,506 shares. Daiwa Secs Gp, a Japan-based fund reported 157,835 shares. Perella Weinberg Prns Cap Mgmt LP invested in 6,928 shares or 0.05% of the stock. Wisconsin-based Legacy Ptnrs has invested 0.4% in Gilead Sciences, Inc. (NASDAQ:GILD). Fosun Int Ltd holds 1% or 123,759 shares in its portfolio. Oppenheimer Asset Mgmt accumulated 6,529 shares. Fmr Ltd Liability Corp, Massachusetts-based fund reported 27.71M shares. Monarch Cap Mngmt has invested 1.68% in Gilead Sciences, Inc. (NASDAQ:GILD). Violich Cap invested in 86,931 shares or 1.92% of the stock. New York State Common Retirement Fund holds 0.4% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 3.82M shares. Highland Capital Management Ltd Com reported 38,372 shares. Financial Counselors accumulated 12,093 shares.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 21 have Buy rating, 0 Sell and 9 Hold. Therefore 70% are positive. Gilead Sciences had 124 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, July 25 by Cowen & Co. On Friday, July 29 the stock rating was downgraded by Argus Research to “Hold”. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Hold” rating given on Monday, August 28 by BMO Capital Markets. BMO Capital Markets maintained Gilead Sciences, Inc. (NASDAQ:GILD) on Friday, July 21 with “Hold” rating. The rating was upgraded by Citigroup on Tuesday, January 30 to “Buy”. The rating was maintained by Mizuho with “Buy” on Wednesday, November 8. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Buy” rating by Berenberg on Thursday, September 22. RBC Capital Markets maintained the shares of GILD in report on Wednesday, February 7 with “Buy” rating. As per Friday, February 5, the company rating was initiated by Leerink Swann. The stock has “Outperform” rating by BMO Capital Markets on Friday, October 27.

Since August 30, 2017, it had 0 insider buys, and 13 insider sales for $51.09 million activity. 50,000 Gilead Sciences, Inc. (NASDAQ:GILD) shares with value of $4.18M were sold by MARTIN JOHN C. 51,820 shares valued at $4.40M were sold by Washington Robin L on Thursday, September 7. Meyers James R sold $4.99M worth of stock.

Analysts await CRA International, Inc. (NASDAQ:CRAI) to report earnings on March, 7. They expect $0.34 earnings per share, up 41.67% or $0.10 from last year’s $0.24 per share. CRAI’s profit will be $2.76 million for 33.04 P/E if the $0.34 EPS becomes a reality. After $0.41 actual earnings per share reported by CRA International, Inc. for the previous quarter, Wall Street now forecasts -17.07% negative EPS growth.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>